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Abstract
Background: The accessory gene regulator (agr) is a quorum sensing cluster of genes which control colonization
and virulence in Staphylococcus aureus. We evaluated agr function in community- (CA) and healthcare-associated
(HA) MRSA, to compare the pharmacodynamics and bactericidal activity of vancomycin against agr functional and
dysfunctional HA-MRSA and CA-MRSA.
Methods: 40 clinical isolates of MRSA from the Canadian Nosocomial Infection Surveillance Program were
evaluated for delta-haemolysin production, as a surrogate marker of agr function. Time kill experiments were
performed for vancomycin at 0 to 64 times the MIC against an initial inoculum of 10
6 and 10
8 cfu/ml of agr
functional and dysfunctional CA-MRSA and HA-MRSA and these data were fit to a hill-type pharmacodynamic
model.
Results: 15% isolates were agr dysfunctional, which was higher among HA-MRSA (26.3%) versus CA-MRSA (4.76%).
Against a low initial inoculum of 10
6 cfu/ml of CA-MRSA, vancomycin pharmacodynamics were similar among agr
functional and dysfunctional strains. However, against a high initial inoculum of 10
8 cfu/ml, killing activity was
notably attenuated against agr dysfunctional CA-MRSA (USA400) and HA-MRSA (USA100). CA-MRSA displayed a
20.0 fold decrease in the maximal reduction in bacterial counts (Emax) which was 3.71 log10 CFU/ml for agr
functional vs. 2.41 log10 CFU/ml for agr dysfunctional MRSA (p = 0.0007).
Conclusions: Dysfunction in agr was less common among CA-MRSA vs. HA-MRSA. agr dysfunction demonstrated
an impact on vancomycin bactericidal activity and pharmacodynamics against a high initial inoculum of CA-MRSA
and HA-MRSA, which may have implications for optimal antimicrobial therapy against persistent, difficult to treat
MRSA infections.
Background
The accessory gene regulator (agr) is a quorum sensing
cluster of genes which orchestrate the expression of cell-
secreted and virulence factors, and several metabolic
pathways in Staphylococcus aureus in a growth depen-
dant fashion [1,2]. It has been hypothesized that S. aureus
which exhibit agr dysfunction may possess an intrinsic
survival advantage: these strains have demonstrated van-
comycin tolerance and a proclivity to develop heteroge-
neous resistance under vancomycin selective pressure
[3,4]. However, agr dysfunction has primarily been evalu-
ated in strains of healthcare-associated (HA) MRSA
w h e r ead o w n - r e g u l a t e dagr locus has been associated
with prolonged and persistent bactaeremia [5,6].
Worldwide, the incidence of community-associated
(CA) MRSA is rapidly increasing with the emergence of
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proportion of HA-MRSA display dysfunctional in the
agr loci, the prevalence of agr dysfunction among CA-
MRSA is relatively low from 3.5 to 9% [10,11]. Although
this may account for the enhanced virulence of CA-
MRSA as compared with HA-MRSA, whether dysfunc-
tion in agr would hamper vancomycin bactericidal activ-
ity among Canadian CA-MRSA has not been fully
elucidated. Therefore, the objectives of this current
study were to compare vancomycin pharmacodynamics
of agr dysfunctional versus functional CA-MRSA and
HA-MRSA clinical isolates from the Canadian Nosoco-
mial Infection Surveillance Program at low and high
initial inoculum.
Methods
Bacterial Isolates
40 clinical methicillin-resistant S. aureus (MRSA) iso-
lates were selected for analysis obtained from the Cana-
dian Nosocomial Infection Surveillance Program
(CNISP), as shown in Table 1. Isolates were previously
subtyped by using pulsed-field gel electrophoresis
(PFGE) as previously described by Simor et.al. [8]. A
community-associated isolate was defined as one which
had a USA300/Canadian-MRSA-10 or USA400/Cana-
dian-MRSA-7 PFGE profile, according to the nomencla-
ture established by Simor et. al. and McDougal et. al.
[8,12]. Isolates with other PFGE profiles were considered
to be healthcare-associated. All isolates were evaluated
for agr dysfunction using delta-haemolysin production
as a surrogate marker of agr function using RN4220, as
previously described [4]. Four strains subsequently were
selected including two CA-MRSA (CA-MRSA 26, agr
functional, USA300/Canadian-MRSA-10 and CA-MRSA
20, agr dysfunctional, USA400/Candian-MRSA-7) and
two HA-MRSA (HA-MRSA 7, agr functional, USA100/
Canadian-MRSA-2 and HA-MRSA 9, agr dysfunctional,
USA100/Canadian-MRSA-2) for vancomycin time killing
experiments. The PFGE profile of all isolates were
blinded to the investigators performing time killing
experiments (R.M. and B.T.) until final analyses were
completed.
Antimicrobial, Media, and MIC Determination
Vancomycin (obtained from Sigma Chemical Company,
St. Louis, Missouri) stock solutions were freshly pre-
pared prior to each experimental run for all experi-
ments. Minimum inhibitory concentrations were
determined for each isolate in duplicate by microdilu-
tion techniques according to the guidelines of the Clini-
cal and Laboratory Standards Institute (CLSI). Brain
Heart Infusion broth (Difco, Detroit, MI) was utilized
for time-kill experiments. Quantification of colony
counts were determined using Tryptic Soy Agar II plates
with 5% sheep Blood (BD, Franklin Lakes, NJ ).
Time Kill Experiments
Selective time-kill experiments were performed in dupli-
cate for vancomycin against agr functional and dysfunc-
tional CA-MRSA and HA-MRSA using methodology as
previous described[13]. Briefly, fresh bacterial colonies
from an overnight growth were added to normal saline
and adjusted spectrophotometrically to provide a stan-
dard suspension. This suspension was diluted with BHI
and antibiotic stock solutions to achieve a starting
inoculum of approximately 10
6 or 10
8 CFU/ml. Vanco-
mycin concentrations of 0, 0.25, 1, 4, 16, and 64 times
the MIC were tested against all isolates. Each 10-ml cul-
ture was incubated in a water bath at 35°C with con-
stant shaking, and 0.1-ml samples were withdrawn for
the determination of bacterial counts at 0, 4,8 and 24 h.
Colony counts were determined by plating 50 μl of each
diluted sample onto BHI agar (Becton Dickinson, Frank-
lin Lakes, NJ) with an automated spiral dispenser
(WASP; Don Whitley Scientific Limited, West York-
shire, England) and incubating the plates for 24 h at 35°
C to confirm colony counts.
Pharmacokinetic and Pharmacodynamic Analyses
For each regimen tested, pharmcodynamic analysis was
performed as previously described[13] using the Log
Ratio Change comparing the changes in cfu/ml from 0
(CFU0h ) versus 24 h (CFU24 h) and calculated as shown
in equation 1.
Log Ratio change = log10

CFU24h
CFU0h

(1)
Using non-linear regression a four-parameter concen-
tration-effect Hill-type model was fit to the effect para-
meter Systat (Version 11, Richmond, VA) using:
E=E 0-
Emax × [C:MIC]H
[EC50]H + [C:MIC]H (2)
Table 1 Bacterial isolates utilized in this study
Community or
Healthcare Associated
PFGE
Profile (USA)
PFGE
Profile (CANADA)
CA-MRSA (n = 21)* USA300 (n = 15) CMRSA-10 (n = 15)
USA400 (n = 6) CMRSA-7 (n = 6)
HA-MRSA (n = 19)** USA100 (n = 8) CMRSA-2 (n = 8)
USA500 (n = 3) CMRSA-5 (n = 3)
USA600 (n = 6) CMRSA-1 (n = 6)
Other No USA Correlate (n = 2) CMRSA-9 (n = 2)
*No CA-MRSA were agr dysfunctional
**6 HA-MRSA were agr dysfunctional,belonging to USA 100 (n = 1), USA 400
(n = 1), and USA 500 (n = 2), and USA 600(n = 2) PFGE profile. The remaining
strains were classified as agr functional
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effect relationship, was utilized to characterize the rela-
tionship between the decrease in bacterial counts from
0 to 24 h as characterized by the Log Ratio Change. The
dependent variable (E, Effect) was the Log Ratio Change
measuring the reduction in bacterial counts for each
regimen comparing 0 h to 24 h, E0 is the measured
effect at zero drug concentration which is an assessment
of bacterial growth with no vancomycin, Emax is the
maximal effect which describes the maximal reduction
of bacterial counts in log10 CFU/ml , C:MIC is concen-
tration of vancomycin divided by its respective MIC,
EC50 is the effective concentration of vancomycin for
which there is 50% maximal effect, H is the slope con-
stant also described as the Hill or sigmoidicity constant.
Statistical comparisons among each model fitted para-
meter were performed using the t-test (Systat 11, Rich-
mond, VA), for which a p value of <0.05 was considered
significant.
Results
Vancomycin MICs against HA-MRSA 7, 9, were 1.0, 2.0
mg/L and for CA-MRSA 26 and 20 were 1.0, and 1.0
mg/L. 15% (6 of 40) of isolates were dysfunctional in
agr which was higher among HA-MRSA (26.3%, 5 of
19) vs. CA-MRSA (4.76%, 1 of 21, USA 400/Canadian
MRSA 7). The activity of vancomycin against a low (10
6
cfu/ml) and high (10
8 cfu/ml) initial inoculum of bacter-
ial strains is depicted in Figure 1. agr functional strains
(CA-MRSA 26) displayed greater killing versus agr dys-
functional MRSA (CA-MRSA 20). Maximal bacterial
reductions at 64 times the MIC for CA-MRSA 20 and
C A - M R S A2 6w e r e3 . 3 0a n d3 . 0 1l o g 10 cfu/ml at 24 h,
respectively. However, against 10
6 cfu/ml inoculum dif-
ferences in vancomycin killing of HA-MRSA with
respect to agr function were noted with less activity ver-
sus agr dysfunctional strains. Interestingly, against a
high initial inoculum of MRSA, vancomycin did not
achieve bactericidal activity against any isolate. Most
notably, against 10
8 cfu/ml, the killing activity of vanco-
mycin against agr functional versus dysfunctional strains
consistently differed for both CA-MRSA and HA-MRSA
strains. Greater vancomycin killing activity occurred
against agr functional (HA-MRSA 7, CA-MRSA 26) ver-
sus dysfunctional (HA-MRSA 9, CA-MRSA 20) strains.
Reductions in bacterial counts at 24 h were greater
against HA-MRSA 7 versus HA-MRSA 9 with 1.87 ver-
sus 1.24 log10 CFU/ml reduction at 24 h. Against CA-
MRSA 20, killing approached the bactericidal threshold
with a 2.63 log10 cfu/ml reduction as compared with
C A - M R S A2 6w h e r ead e c r e a s eo fo n l y1 . 2 5l o g 10 cfu/
ml at 24 h was demonstrated.
Analysis of pharmacodynamics (PD) revealed excellent
model fits of the data to the Hill model. R
2 for was
>0.99 for all MRSA isolates at both initial inoculum.
The concentration effect profile is depicted in Figure 2
with maximal likelihood fitted parameters from equation
2. Reduction in bacterial counts with vancomycin
occurred in a concentration-dependent manner, as seen
with the steep sigmoidicity constant (H) and low EC50
against most isolates. All pharmacodynamic parameter
estimates consistently differed for both HA-MRSA and
CA-MRSA when comparing agr functional versus dys-
functional isolates at the higher starting inoculum (10
8).
There were significant differences in regards to vanco-
mycin activity in reducing bacterial counts when com-
paring agr function and dysfunctional strains among
HA-MRSA and CA-MRSA. HA-MRSA isolates dis-
played a 2.89 fold decrease in the maximal reduction in
bacterial counts (Emax) which was 2.91 log10 CFU/ml
for agr functional vs. 2.45 log10 CFU/ml for agr dysfunc-
tional MRSA log10 CFU/ml (p = 0.0163).
CA-MRSA displayed an even greater trend with a 20.0
fold decrease in the maximal reduction in bacterial
counts (Emax) which was 3.71 log10 CFU/ml for agr
functional vs. 2.41 log10 CFU/ml for agr dysfunctional
MRSA (p = 0.0007). The sigmoidicity constant (H) was
nearly three times higher and EC50 values were consis-
tently lower in agr functional versus dysfunctional
isolates, but did not achieve significance. Model fitted
for each isolate parameter estimates from Equation 2 in
Figure 2.
Discussion
The epidemiology of Staphylococcus aureus is rapidly
changing. Highly virulent strains of CA-MRSA have
emerged worldwide and have been associated with fatal
infections in a plethora of recent outbreaks including
severe necrotizing pneumonia and fasciitis and in both
children and healthy adults [8,9,14]. A number of viru-
lence determinants have recently been characterized in
CA-MRSA including alpha-type phenol soluble modules
(PSMs), the arginine catabolic mobile element (ACME),
the panton- valentine leucocidin cytotoxin and a variety
of virulence factors not common in HA-MRSA[15-17].
Interestingly, many of these virulence determinants are
regulated via the two component agr system, the master
regulator of S. aureus, controlling growth, colonization
and virulence[1,17,18]. However, although agr dysfunc-
tion in S. aureus may potentially decrease virulence, the
loss of agr function may increase the proclivity to
develop vancomycin tolerance and resistance, although
this has not been previously evaluated in strains of CA-
MRSA. Therefore, we sought to determine if dysfunc-
tional agr strains in either HA-MRSA and CA-MRSA
would impact vancocmycin pharmacodynamics.
In the current investigation, agr dysfunction resulted in
attenuation of vancomycin killing activity with decreases
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Figure 1 Time kill experiments evaluating the bactericidal activity of vancomycin versus agr functional HA-MRSA 7 (A,E), agr
dysfunctional HA-MRSA 9 (B,F), agr functional CA-MRSA 26 (C,G), and agr dysfunctional CA-MRSA 20 (D,H) at low and high initial
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Figure 2 Pharmacodynamic relationship evaluating vancomycin concentration to minimum inhibitory concentration ratio (C:MIC) and
change in log10 CFU/ml at 24 hours (Log Ratio Change) among agr functional HA-MRSA 7 (A,E), agr dysfunctional HA-MRSA 9 (B,F),
agr functional CA-MRSA 26 (C,G), and agr dysfunctional CA-MRSA 20 (D,H) at low and high initial inoculum (10
6,1 0
8 log10 cfu/ml).R
2:
Coefficient of Determination. Data are reported as maximum likelihood model fitted parameter estimates from equation 2 for each strain.
Tsuji et al. Annals of Clinical Microbiology and Antimicrobials 2011, 10:20
http://www.ann-clinmicrob.com/content/10/1/20
Page 5 of 7in maximal effect and lack of bactericidal activity against
both HA-MRSA and CA-MRSA. We also determined
that strains which exhibited agr dysfunction were far less
common among CA-MRSA vs. HA-MRSA, with only
one out of 18 isolates demonstrating this phenomena.
Taken together, these findings may have potential impli-
cations for the use of vancomycin for the treatment of
CA-MRSA infections. First, although reports of persistent
bacteraemia, vancomycin treatment failure and heteroge-
neous resistance have been primarily in HA-MRSA, the
findings of the present study highlight similarities of
CA-MRSA and HA-MRSA when exposed to vancomycin
[5,6]. Similar to previous reports in HA-MRSA, limited
bacterial killing was evident by vancomcyin against
CA-MRSA, especially in the context of agr dysfunction.
Second, with reports of CA-MRSA as an emerging patho-
gen in infections that are sequestered or deep-seated,
such as endocarditis, the potential for attenuation of bac-
tericidal activity should be considered when vancomycin
is utilized against a high initial inoculum of CA-MRSA
[19]. Therefore, the inoculum effect displayed by vanco-
mycin displays may be a potential explanation for the
lack of bactericidal activity shown in this study. This is
especially important to consider since eradication of S.
aureus from sites of infection that are at high bacterial
density or in a biofilm matrix at may be particularly diffi-
cult for vancomycin due to its pharmacodynamics prop-
erties, including slow bactericidal activity and the
heterogeneous nature of vancomycin resistance. Finally,
as the antimicrobial susceptibility profile of CA-MRSA is
commonly greater than HA-MRSA and with initial
reports of heterogeneous vancomycin-intermediate resis-
tance in CA-MRSA emerging[20], the treatment of agr
dysfunctional CA-MRSA may favor the use of combina-
tion therapy or alternative agents rather than glycopep-
tide monotherapy.
Potential limitations of this study include the limited
number of strains including only two CA-MRSA and
two HA-MRSA isolates which were utilized to evaluate
vancomycin efficacy. We also acknowledge the lack of
inclusion of a USA300 strain in time kill experiments
because there were no agr dysfunctional CA-MRSA
strains among the 40 isolates which we screened. Inter-
estingly, these data corroborate our previous work
which also shows an exceptionally low prevalence (2.5%)
of agr dysfunction in community isolates of MRSA.
Therefore, further in vitro and in vivo studies are neces-
sary to confirm these findings in additional CA-MRSA
before these results are applied to clinical practice.
Conclusions
This study is the first to demonstrate that vancomycin
activity was impaired against a high inoculum of both
community and healthcare associated strains of MRSA
that were dysfunctional in agr. Additionally this study
characterized the function on agr among MRSA strains
which were genetically defined according to commu-
nity and hospital original and determined that agr dys-
function were far less common among CA-MRSA as
compared with HA-MRSA (11). These result are
important to consider particularly in the treatment of
infections of high bacteriald e n s i t yd u et oM R S Aw h e n
vancomycin is utilized against a high initial inoculum
of CA-MRSA
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